Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus-Reference-Cited by-同舟云学术

Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus

Published:2024 Issue:4 Volume:5 Page:1473-1479
ISSN:2633-5409
Container-title:Materials Advances
language:en
Short-container-title:Mater. Adv.

Author:

Zhao Zhongchao¹²³^ORCID,Chung Young Hun³⁴^ORCID,Steinmetz Nicole F.¹²³⁴⁵^ORCID

Affiliation:

1. Department of NanoEngineering, University of California, 9500 Gilman Dr, La Jolla, San Diego, CA, 92093, USA

2. Center for Nano-ImmunoEngineering, University of California, 9500 Gilman Dr, La Jolla, San Diego, CA, 92093, USA

3. Moores Cancer Center, University of California, 9500 Gilman Dr, La Jolla, San Diego, CA, 92093, USA

4. Department of Bioengineering, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA

5. Department of Radiology, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA

Abstract

We have developed nanoparticle formulations targeting M2 macrophages for cancer immunotherapy by conjugating high-affinity binding peptides to cowpea mosaic virus as an immunostimulatory adjuvant.

Funder

National Cancer Institute

National Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MA/D3MA00820G

Reference46 articles.

1. Releasing the Brakes on Cancer Immunotherapy

2. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

3. Acquired Resistance to Immune Checkpoint Inhibitors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses;International Journal of Molecular Sciences;2024-04-11